Intracranial Hemorrhage Associated With Revascularization Therapies
暂无分享,去创建一个
[1] J. Broderick,et al. Microcatheter Contrast Injections During Intra-Arterial Thrombolysis May Increase Intracranial Hemorrhage Risk , 2008, Stroke.
[2] E. Lo,et al. Triggers and mediators of hemorrhagic transformation in cerebral ischemia , 2003, Molecular Neurobiology.
[3] W. Smith,et al. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. , 2006, AJNR. American journal of neuroradiology.
[4] K. Furie,et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke , 2006, Neurology.
[5] J. Koziol. NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.
[6] Michael D Hill,et al. Extent of Early Ischemic Changes on Computed Tomography (CT) Before Thrombolysis: Prognostic Value of the Alberta Stroke Program Early CT Score in ECASS II , 2006, Stroke.
[7] A. Buchan,et al. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[8] J. Grotta,et al. NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.
[9] P. Trouillas,et al. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. , 2006, Stroke.
[10] Ims Study Investigators. Hemorrhage in the Interventional Management of Stroke Study , 2006, Stroke.
[11] H. Koennecke. Cerebral microbleeds on MRI , 2006, Neurology.
[12] F. Munschauer,et al. Hyperglycemia, Insulin, and Acute Ischemic Stroke: A Mechanistic Justification for a Trial of Insulin Infusion Therapy , 2006, Stroke.
[13] GötzThomalla,et al. Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (≥80 Years) Stroke Patients , 2005 .
[14] J. Röther,et al. Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (≥80 Years) Stroke Patients , 2005, Stroke.
[15] Andrea Kassner,et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. , 2005, AJNR. American journal of neuroradiology.
[16] Brian Silver,et al. Importance of Early Ischemic Computed Tomography Changes Using ASPECTS in NINDS rtPA Stroke Study , 2005, Stroke.
[17] H. Lutsep,et al. Safety and Efficacy of Mechanical Embolectomy in Acute Ischemic Stroke: Results of the MERCI Trial , 2005, Stroke.
[18] Dong Gyu Na,et al. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. , 2005, AJNR. American journal of neuroradiology.
[19] A. Demchuk,et al. Derivation of Transcranial Doppler Criteria for Rescue Intra-arterial Thrombolysis: Multicenter Experience From the Interventional Management of Stroke Study , 2005, Stroke.
[20] Abciximab Emergent Stroke Treatment Trial Investigators,et al. Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial , 2005, Stroke.
[21] G. Schlaug,et al. Markedly Reduced Apparent Blood Volume on Bolus Contrast Magnetic Resonance Imaging as a Predictor of Hemorrhage After Thrombolytic Therapy for Acute Ischemic Stroke , 2005, Stroke.
[22] J. Grotta,et al. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. , 2005, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[23] P. Lyden,et al. A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke , 2005, Stroke.
[24] A. Buchan. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial , 2005 .
[25] S. Warach,et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.
[26] Fernando Vinuela,et al. MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia , 2004, Stroke.
[27] A. Alexandrov,et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. , 2004, The New England journal of medicine.
[28] K. Furie,et al. Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke , 2004, Stroke.
[29] S. Warach,et al. Evidence of Reperfusion Injury, Exacerbated by Thrombolytic Therapy, in Human Focal Brain Ischemia Using a Novel Imaging Marker of Early Blood–Brain Barrier Disruption , 2004, Stroke.
[30] John A Butman,et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. , 2004, JAMA.
[31] J. Arenillas,et al. Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator , 2004, Stroke.
[32] S. Pedraza,et al. Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke , 2004, Stroke.
[33] A. Woolfenden,et al. Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1): A Randomized, Placebo-Controlled Safety Study , 2004, Stroke.
[34] P. Adeleine,et al. Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases , 2004, Stroke.
[35] L. Price,et al. In Acute Ischemic Stroke, Are Asymptomatic Intracranial Hemorrhages Clinically Innocuous? , 2004, Stroke.
[36] J. Seo,et al. Contrast Enhancement and Contrast Extravasation on Computed Tomography After Intra-Arterial Thrombolysis in Patients With Acute Ischemic Stroke , 2004, Stroke.
[37] Ims Study Investigators. Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study , 2004, Stroke.
[38] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[39] D. Krieger,et al. Mild to Moderate Hypothermia Prevents Microvascular Basal Lamina Antigen Loss in Experimental Focal Cerebral Ischemia , 2004, Stroke.
[40] D. Tanné,et al. Dosing errors may impact the risk of rt-PA for stroke: the Multicenter rt-PA Acute Stroke Survey. , 2004, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[41] A. Buchan,et al. Selection of Acute Ischemic Stroke Patients for Intra-Arterial Thrombolysis With Pro-Urokinase by Using ASPECTS , 2003, Stroke.
[42] J. Weinberger. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. , 2003, Current cardiology reports.
[43] A. Weill,et al. North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. , 2003, AJNR. American journal of neuroradiology.
[44] J. Arenillas,et al. Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.
[45] J. Serena,et al. Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.
[46] J. Arenillas,et al. Thrombolysis-Related Hemorrhagic Infarction: A Marker of Early Reperfusion, Reduced Infarct Size, and Improved Outcome in Patients With Proximal Middle Cerebral Artery Occlusion , 2002, Stroke.
[47] Andrew M. Demchuk,et al. Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice: The Multicenter rt-PA Acute Stroke Survey , 2002, Circulation.
[48] G. Samsa,et al. Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). , 2002, Journal of evaluation in clinical practice.
[49] P. Lapchak. Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment , 2002, Current neurology and neuroscience reports.
[50] J. Grotta,et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. , 2001, JAMA.
[51] Taku Sugawara,et al. Matrix Metalloproteinase Inhibition Prevents Oxidative Stress-Associated Blood–Brain Barrier Disruption after Transient Focal Cerebral Ischemia , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[52] R. Higashida,et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke , 2001, Neurology.
[53] W. Hacke,et al. Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic? , 2001, Stroke.
[54] M. Moseley,et al. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging. , 2001, Archives of neurology.
[55] Erich Bluhmki,et al. Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.
[56] M. Hommel,et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. , 2000, Stroke.
[57] P. Akins,et al. Intra-arterial prourokinase for acute ischemic stroke. , 2000, JAMA.
[58] E. Berge,et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study , 2000, The Lancet.
[59] S Hamilton,et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. , 2000, Stroke.
[60] E. Berge,et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. , 2000, Lancet.
[61] R. Higashida,et al. Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .
[62] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[63] J. Grotta,et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. , 1999, Stroke.
[64] L Bozzao,et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. , 1999, Stroke.
[65] J. Sunshine,et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. , 1999, Stroke.
[66] A. Demchuk,et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. , 1999, Stroke.
[67] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[69] R. Higashida,et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. , 1998, Stroke.
[70] A. Alexandrov,et al. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. , 1997, Stroke.
[71] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[72] V Larrue,et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.
[73] T. N. t-P. S. S. Group,et al. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. , 1997, Stroke.
[74] T. N. t-P. S. S. Group,et al. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. , 1997, Stroke.
[75] M. Hommel,et al. Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.
[76] G. Sette,et al. Hemorrhagic transformation of brain infarct , 1996, Neurology.
[77] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[78] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[79] L. Munari,et al. RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .
[80] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[81] P. Toutouzas,et al. Percutaneous implantation of autologous vein graft stent for treatment of coronary artery disease , 1995, The Lancet.
[82] J. Broderick,et al. Factors Related to Intracranial Hematoma Formation in Patients Receiving Tissue‐Type Plasminogen Activator forAcute Ischemic Stroke , 1994, Stroke.
[83] Lyden Pd,et al. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. , 1993, Cerebrovascular and brain metabolism reviews.
[84] P. Lyden,et al. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. , 1993, Cerebrovascular and brain metabolism reviews.
[85] M. Pessin,et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. , 1993, AJNR. American journal of neuroradiology.
[86] Clinical‐radiographic correlations within the first five hours of cerebral infarction , 1992, Acta neurologica Scandinavica.
[87] W. Hacke,et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.
[88] M. Pessin,et al. Thrombolytic agents in the treatment of stroke. , 1990, Clinical neuropharmacology.
[89] M. Fujishima,et al. Hemorrhagic transformation in cerebral embolism. , 1989, Stroke.
[90] C. Hornig,et al. Hemorrhagic cerebral infarction--a prospective study. , 1986, Stroke.
[91] B. J. Sussman,et al. Thrombolysis with fibrinolysin in cerebral arterial occlusion. , 1958, Journal of the American Medical Association.
[92] R. D. Adams. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. , 1950, The Journal of clinical investigation.